Akemi Ishida‐Yamamoto

Akemi Ishida‐Yamamoto

Auto-generated profile, based on publicly available information

Akemi Ishida‐Yamamoto

Department of Dermatology Asahikawa Medical University Asahikawa Japan

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2005 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
PDF file
AIAkemi Ishida-Yamamoto
Akemi Ishida-Yamamoto
CDCéline Deraison
Céline Deraison
CBChrystelle Bonnart
Chrystelle Bonnart
EBEmmanuelle Bitoun
Emmanuelle Bitoun
RRRoss Robinson
Ross Robinson
AHAlain HOVNANIAN
Alain HOVNANIAN

1 May 2004 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
PDF file
AIAkemi Ishida-Yamamoto
Akemi Ishida-Yamamoto
MSMichel Simon
Michel Simon
MKMari Kishibe
Mari Kishibe
YMYuki Miyauchi
Yuki Miyauchi
HTHidetoshi Takahashi
Hidetoshi Takahashi
HIHajime Iizuka
Hajime Iizuka

1 May 2025 in British Journal of Dermatology
Verified
Journal Article
Open access
MAMasashi Akiyama
Masashi Akiyama
KCKeith Choate
Keith Choate
ÁHÁngela Hernández-Martín
Ángela Hernández-Martín
MAMandy Aldwin-Easton
Mandy Aldwin-Easton
BCBodemer Christine
Bodemer Christine
Judith FischerJudith Fischer
Judith Fischer
Epidermal differentiation disorders (EDDs) encompass inherited conditions characterized by abnormal epidermal differentiation, including nonsyndromic and syndromic subtypes with more extensive cutaneous involvement or palmoplantar keratoderma. Nonsyndromic EDDs (nEDDs) are defined as disorders that primarily affect large areas of skin and adnexal structures without alterations in extracutaneous tissues resulting from the underlying genetic change. To facilitate the development of targeted therapies and to provide clinicians with clearer therapeutic guidance, we have developed a new nomenclature for EDDs that includes the causative altered gene and the nEDD subgroup designation, sometimes with a clinical or histological descriptor or acronym. Historically, many nEDDs have been named on the basis of phenotypic characteristics or associations that are now considered outdated or inappropriate. For example, the term ‘harlequin ichthyosis’ evokes potentially stigmatizing images. Similarly, the word ‘ichthyosis’ is derived from the Greek ichthys, meaning fish, and the Greek hystrix, meaning porcupine, further emphasizing the need to abandon derogatory terminology. As a result, the clinical relevance of the previous classification, which included eponymous and/or descriptive titles, has diminished. In the new, gene-based classification, old terms considered pejorative, such as ichthyosis, vulgaris, hystrix and harlequin have been eliminated and eponyms have been replaced. Among the 53 genetically distinct nEDDs are conditions formerly known as autosomal recessive congenital ichthyosis, erythrokeratodermia variabilis et progressiva, Hailey–Hailey disease and Darier–White disease. This review outlines the updated nomenclature and classifications of nEDDs, linked to detailed clinical descriptions and representative photographs to guide practitioners.

19 November 2014 in Cell and tissue research
Verified
Journal Article
Closed access
PDF file
AIAkemi Ishida-Yamamoto
Akemi Ishida-Yamamoto
SISatomi Igawa
Satomi Igawa

4 May 2011 in The Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
AIAkemi Ishida-Yamamoto
Akemi Ishida-Yamamoto
SISatomi Igawa
Satomi Igawa
MKMari Kishibe
Mari Kishibe

4 April 2025 in British Journal of Dermatology
Verified
Journal Article
Open access
Amy PallerAmy Paller
Amy Paller
JTJoyce Teng
Joyce Teng
JMJuliette Mazereeuw-Hautier
Juliette Mazereeuw-Hautier
ÁHÁngela Hernández-Martín
Ángela Hernández-Martín
CTCéline Granier Tournier
Céline Granier Tournier
MSMatthias Schmuth
Matthias Schmuth
Since the 2010 classification of ichthyoses, our understanding of hereditary epidermal differentiation disorders (EDDs) has markedly increased, allowing for consideration of new therapeutic targets based on disease pathogenesis. A new gene- and protein product function-based classification focuses on shared mechanisms of disease pathogenesis, with the possibility that grouped disorders may respond similarly to new therapeutics. These EDDs have been subdivided into syndromic (sEDD), nonsyndromic with features limited to skin and appendages, and predominantly palmoplantar skin involvement (nonsyndromic and syndromic). sEDDs have clinically important extracutaneous features related to the gene alteration. Often, recognition based on skin manifestations facilitates early gene-based diagnosis, discussion of prognosis, genetic counselling and the initiation of therapy. All sEDDs are rare; the most common are STS-sEDD (formerly known as X-linked ichthyosis) and SPINK5-sEDD (formerly known as Netherton syndrome). Given the rarity, frequent association with early demise and variable clinical features of sEDDs, the natural history of the diseases with advancing age and genotype–phenotype relationships are poorly defined. Of the 51 sEDDs, associated neurological (n = 36; 71%) and/or ophthalmological (n = 25; 49%) findings are most common, and 39% (n = 20) have associated hair abnormalities. The widespread use of topical lovastatin for cholesterol synthesis-related sEDDs represents the prototype of pathogenesis-based therapy. This concept of upstream inhibition to prevent metabolite accumulation and supplementation with the pathway end product potentially applies to other sEDDs, such as those affecting ceramide synthesis and transport. Topical or systemically administered inhibition of activated pathways is another potential approach, exemplified by the emerging treatment of SPINK5-sEDD with kallikrein inhibitors. Many sEDDs may be amenable to gene editing or the introduction of functional cDNA. However, even systemic treatments targeting cutaneous diseases may not address extracutaneous manifestations that arise during embryological development.